ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer

Four weeks ago, Seagen and Astellas made waves when they revealed that the pairing of Padcev with Merck’s oncology superstar Keytruda had achieved improved outcomes over standard of care in patients with previously untreated bladder cancer.